{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:38:42Z","timestamp":1790098722639,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40265-024-02023-6","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:01:58Z","timestamp":1711407718000},"page":"613-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Danicopan: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"2023_CR1","unstructured":"Alexion Pharma LLC. Voydeya (Danicopan) 50mg: Japanese prescribing information. 2024. https:\/\/www.info.pmda.go.jp. Accessed 8 Mar 2024."},{"issue":"Suppl. 4","key":"2023_CR2","first-page":"S33","volume":"98","author":"AG Kulasekararaj","year":"2023","unstructured":"Kulasekararaj AG, Lazana I. Paroxysmal nocturnal hemoglobinuria: where are we going. Am J Hematol. 2023;98(Suppl. 4):S33\u201343.","journal-title":"Am J Hematol"},{"key":"2023_CR3","unstructured":"AstraZeneca. Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy [media release]. 19 Jan 2024. https:\/\/www.astrazeneca.com."},{"key":"2023_CR4","unstructured":"Pharmaceuticals and Medical Devices Agency. Danicopan. 2024. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/39990E6. Accessed 8 Mar 2024."},{"key":"2023_CR5","unstructured":"European Medicines Agency. First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria. 2024. https:\/\/www.ema.europa.eu\/en\/news\/first-oral-treatment-against-residual-haemolytic-anaemia-patients-paroxysmal-nocturnal-haemoglobinuria. Accessed 8 Mar 2024."},{"key":"2023_CR6","unstructured":"Alexion AstraZeneca Rare Disease. Pipeline. 2024. https:\/\/alexion.com\/our-research\/pipeline. Accessed 8 Mar 2024."},{"key":"2023_CR7","unstructured":"Alexion Pharmaceuticals. Alexion completes acquisition of Achillion [media release]. 29 Jan 2020. http:\/\/www.alexion.com."},{"key":"2023_CR8","unstructured":"AstraZeneca. Acquisition of Alexion completed [media release]. 21 July 2021. http:\/\/www.astrazeneca.com."},{"key":"2023_CR9","unstructured":"Alexion AstraZeneca Rare Disease. Danicopan (ALXN2040) add-on to ULTOMIRIS(Rm) (ravulizumab-cwvz) or SOLIRIS(Rm) (eculizumab) met primary endpoint in ALPHA phase III trial for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis [media release]. 16 Sep 2022. http:\/\/www.alexion.com."},{"key":"2023_CR10","unstructured":"Achillion Pharmaceuticals. USPTO grants composition of matter patent to Achillion for small molecule complement alternative pathway factor D inhibitors [media release]. 22 Mar 2017. http:\/\/www.achillion.com. Accessed 22 Mar 2017."},{"key":"2023_CR11","unstructured":"Achillion Pharmaceuticals. USPTO grants composition of matter patent to Achillion for ACH-4471, first-in-class small molecule complement alternative pathway factor D inhibitor [media release]. 25 Oct 2017. http:\/\/www.achillion.com."},{"issue":"12","key":"2023_CR12","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","volume":"106","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(12):3188\u201397.","journal-title":"Haematologica"},{"key":"2023_CR13","first-page":"416","volume":"101","author":"RB Ellis-Pegler","year":"2016","unstructured":"Ellis-Pegler RB, Schwabe C, Ajari I, et al. An orally administered small molecule factor d inhibitor (ACH-4471) for treatment of PNH and complement diseases: preliminary phase 1 results in healthy volunteers. Haematologica. 2016;101:416.","journal-title":"Haematologica"},{"issue":"12","key":"2023_CR14","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","volume":"10","author":"JW Lee","year":"2023","unstructured":"Lee JW, Griffin M, Kim JS, et al. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. Lancet Haematol. 2023;10(12):e955\u201365.","journal-title":"Lancet Haematol."},{"issue":"Suppl. 1","key":"2023_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1182\/blood-2023-189863","volume":"142","author":"A Kulasekararaj","year":"2023","unstructured":"Kulasekararaj A, Griffin M, Piatek CI, et al. Danicopan as add-on therapy to ravulizumab or eculizumab versus placebo in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: phase 3 long-term data. Blood. 2023;142(Suppl. 1):576.","journal-title":"Blood"},{"issue":"20","key":"2023_CR16","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.2021011388","volume":"138","author":"AG Kulasekararaj","year":"2021","unstructured":"Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021;138(20):1928\u201338.","journal-title":"Blood"},{"issue":"10","key":"2023_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","volume":"53","author":"C Nester","year":"2022","unstructured":"Nester C, Appel GB, Bomback AS, et al. Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies. Am J Nephrol. 2022;53(10):687\u2013700.","journal-title":"Am J Nephrol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T14:15:41Z","timestamp":1718892941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02023-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"8 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}